7398-81-4

Basic information

• Product Name: (4-broMoMethylphenyl)acetic acid ethyl ester
• Synonyms: (4-broMoMethylphenyl)acetic acid ethyl ester;ethyl 2-(4-(bromomethyl)phenyl)acetate
• CAS NO: 7398-81-4
• Molecular Formula: C₁₁H₁₃BrO₂
• Molecular Weight: 257.12372
• Mol File: 7398-81-4.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 306.5±22.0 °C(Predicted)
• Appearance: /
• Density: 1.365±0.06 g/cm3(Predicted)
• CAS DataBase Reference: (4-broMoMethylphenyl)acetic acid ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (4-broMoMethylphenyl)acetic acid ethyl ester(7398-81-4)
• EPA Substance Registry System: (4-broMoMethylphenyl)acetic acid ethyl ester(7398-81-4)

Safety Data

• Hazardous Substances Data: 7398-81-4(Hazardous Substances Data)

Usage

Description

(4-bromoMethylphenyl)acetic acid ethyl ester is a chemical compound belonging to the phenylacetic acid family, characterized by its molecular formula C10H11BrO2. It is an ethyl ester derivative of (4-bromoMethylphenyl)acetic acid and is known for its white to off-white solid appearance. With a molecular weight of 257.10 g/mol, the presence of the bromine atom in its structure endows it with versatility as an intermediate in the synthesis of a wide range of chemical compounds with potential pharmacological and biological activities.

Uses

Used in Organic Synthesis:
(4-bromoMethylphenyl)acetic acid ethyl ester serves as a valuable building block in organic synthesis, contributing to the creation of various chemical compounds with diverse applications.
Used in Pharmaceutical Research:
In the pharmaceutical industry, (4-bromoMethylphenyl)acetic acid ethyl ester is utilized for the synthesis of biologically active compounds, playing a crucial role in drug development and the advancement of medicinal chemistry. Its unique structure allows for the exploration of new therapeutic agents with potential applications in treating various health conditions.

Upstream product

• 622-47-9 4-tolylacetic acid 
• 64-17-5 ethanol 
• 14062-19-2 p-tolylacetic acid ethyl ester 
• 13737-36-5 4-bromophenylacetic acid 

Downstream Products

• 1268374-19-1 ethyl 2-(4-((1-benzyl-1H-imidazol-4-yl)methyl)phenyl)acetate 
• 1268374-17-9 ethyl 2-(3-(2-(4-((1-benzyl-1H-imidazol-4-yl)methyl)phenyl)acetamido)-5-(4-ethylbenzyl)phenylamino)-2-oxoacetate 
• 43153-12-4 ethyl 2-(4-formylphenyl)acetate 

Relevant articles and documents

Preparation method of 4-bromomethyl methyl benzoate and derivative thereof

The invention provides a preparation method of methyl 4-bromomethyl benzoate and a derivative thereof, and the method comprises an esterification reaction for converting methyl benzoic acid into methyl benzoate and a bromination reaction for converting the methyl benzoate into the methyl 4-bromomethyl benzoate and the derivative thereof, the brominating agent for the bromination reaction is dibromohydantoin, and the structural formulas of the 4-bromomethyl methyl benzoate and the derivatives thereof are shown in the specification, wherein n1 is equal to 0, 1 or 2; n2 is equal to 1 or 2; according to the preparation method disclosed by the invention, the reaction time can be greatly shortened, the reaction yield is high, and the production efficiency is improved.

Design, synthesis, biological evaluation and in vivo testing of dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors for the treatment of Alzheimer's disease

We have identified chemical probes that act as dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors (>1 log unit difference versus class I HDACs) to decipher the contribution of HDAC isoforms to the positive impact of dua

CONJUGATES AND SMALL MOLECULES WHICH INTERACT WITH THE CD16A RECEPTOR

The invention is related to medicine, in particular, to oncology and immunology. The novel compounds of the general formula 1 or 2, exhibiting affinity for CD16a receptor have been proposed. There were also proposed novel modified proteins active towards